Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specifc cell-permeable peptide inhibitor

Chronic lymphocytic leukemia (CLL) remains an incurable malignancy, urging for the identifcation of new molecular targets for therapeutic intervention. CLL cells rely on overexpression and hyperactivation of the ubiquitous serine/threonine protein kinase CK2 for their viability in vitro. CIGB-300 is...

Descripción completa

Detalles Bibliográficos
Autores principales: Martins, Leila R., Perera, Yasser, Lúcio, Paulo, Silva, Maria G., Perea, Silvio E., Barata, João T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2013
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960206/
https://www.ncbi.nlm.nih.gov/pubmed/24473900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960206/
https://www.ncbi.nlm.nih.gov/pubmed/24473900

Ejemplares similares